Cargando…

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy

Efavirenz is the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line antiretroviral therapy (ART) regimens in low- and middle-income countries, where the prevalence of diabetes is increasing. Randomized control trials have shown mild increases in plasma glucose in participa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karamchand, Sumanth, Leisegang, Rory, Schomaker, Michael, Maartens, Gary, Walters, Lourens, Hislop, Michael, Dave, Joel A., Levitt, Naomi S., Cohen, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782850/ https://www.ncbi.nlm.nih.gov/pubmed/26945366 http://dx.doi.org/10.1097/MD.0000000000002844

Ejemplares similares

Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India
por: Karade, Santosh K., et al.
Publicado: (2016)

High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
por: Deletsu, Selase D., et al.
Publicado: (2020)

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations
por: Sinxadi, Phumla Zuleika, et al.
Publicado: (2016)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

Durability of non-nucleotide reverse transcriptase inhibitor-based first-line ART regimens after 7 years of treatment in rural Uganda: A prospective cohort study
por: Nanfuka, Mastula, et al.
Publicado: (2021)

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings
por: Leisegang, Rory, et al.
Publicado: (2010)

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism
por: Das, Kalyan, et al.
Publicado: (2012)

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Sluis-Cremer, Nicolas
Publicado: (2014)

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
por: Paneth, Agata, et al.
Publicado: (2019)

N(1),N(3)-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
por: Novikov, Mikhail S., et al.
Publicado: (2013)

A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa
por: Leisegang, Rory, et al.
Publicado: (2013)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice
por: Drozd, Daniel R., et al.
Publicado: (2017)

Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis
por: Bezabhe, Woldesellassie M., et al.
Publicado: (2016)

Growth differences by school-age and adolescence according to in utero and peripartum antiretroviral therapy exposure among Ugandan children
por: Awadu, Jorem E., et al.
Publicado: (2023)

Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
por: Leisegang, Rory, et al.
Publicado: (2009)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha, Yu-Jung, et al.
Publicado: (2014)

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2023)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia
por: Jordan, Michael R., et al.
Publicado: (2020)

Antiretroviral treatment failure and associated factors among HIV patients on the first-line antiretroviral therapy at Mizan-Tepi University teaching hospital, Southwest Ethiopia: A cross-sectional study
por: Siraj, Jafer, et al.
Publicado: (2021)

Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings
por: Labhardt, Niklaus D., et al.
Publicado: (2016)

Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals
por: Shilaih, Mohaned, et al.
Publicado: (2017)

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries
por: Tierrablanca, Luis Enrique, et al.
Publicado: (2018)

The investigation of CD4(+)T-cell functions in primary HIV infection with antiretroviral therapy
por: Sun, Yu, et al.
Publicado: (2017)

Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
por: Konishi, Keiji, et al.
Publicado: (2022)

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach
por: Cuzin, Lise, et al.
Publicado: (2015)

Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia
por: Zaki, Eitezaz A., et al.
Publicado: (2020)

Willingness to take and ever use of pre-exposure prophylaxis among female sex workers in Ghana
por: Guure, Chris, et al.
Publicado: (2022)

Immune recovery of middle-aged HIV patients following antiretroviral therapy: An observational cohort study
por: Wong, Ngai Sze, et al.
Publicado: (2017)

HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon
por: Mbouyap, Pretty Rosereine, et al.
Publicado: (2023)

Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India
por: Dravid, Ameet N., et al.
Publicado: (2018)

Trends & predictors of non-AIDS comorbidities among people living with HIV and receiving antiretroviral therapy in Lebanon
por: Abou Hassan, Farouk F., et al.
Publicado: (2022)

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
por: Paneth, Agata, et al.
Publicado: (2017)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study
por: Masiá, Mar, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p0tdol9fbvtfamoi3k7nvqsp9u